7/4/2022  4:48:44 PM Chg. -0.0350 Volume Bid9:59:23 PM Ask9:59:23 PM Market Capitalization Dividend Y. P/E Ratio
1.3850EUR -2.46% 0
Turnover: 0.0000
-Bid Size: - -Ask Size: - 26.67 mill.EUR 0.00% -

Business description

Newron Pharmaceuticals S.p.A. is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the Central Nervous System (CNS) and pain. The Company is headquartered in Bresso near Milan, Italy. Xadago® (safinamide) has received marketing authorization for the treatment of Parkinson’s disease in the European Union, Switzerland, the USA, Australia, Canada, Brazil and Colombia and is commercialized by Newron’s Partner Zambon. US WorldMeds holds the commercialization rights from Zambon for the US. Meiji Seika has the rights to develop and commercialize the compound in Japan and other key Asian territories. In addition to Xadago® for Parkinson’s disease, Newron has a strong pipeline of promising treatments for rare disease patients at various stages of clinical development, including sarizotan for patients with Rett syndrome and ralfinamide for patients with specific rare pain indications. Newron is also developing Evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia.
 

Management board & Supervisory board

CEO
Stefan Weber
Management board
Dennis Dionne, Marco Caremi, Ravi Anand, Roberto Galli
Supervisory board
Dr. Ulrich Köstlin, Donald de Bethizy, Luca Benatti, Patrick Langlois, Stefan Weber
 

Company data

Name: Newron Pharmaceuticals S.p.A.
Address: Via Ludovico Ariosto 21,I-20091 Bresso (Mi)
Phone: +39-02-610-3461
Fax: +39-02-610-34654
E-mail: info@newron.com
Internet: www.newron.com/en
Industry: Healthcare
Sector: Pharmaceutical Industry
Sub sector: Pharmaceuticals
End of financial year: 12/31
Free Float: 91.91%
IPO date: -

Investor relations

Name: Stefan Weber
IR phone: +39-02-610-34609
IR Fax: -
IR e-mail: ir@newron.com

Company calendar

CW 38 | 9/15/2022 Interim Report 2nd Quarter/6 Months
 

Main Shareholders

Freefloat
 
91.91%
Zambon Company S.p.A.
 
4.41%
European Investment Bank
 
3.68%